Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accumulated Depreciation (2016)

Cartesian Therapeutics (RNAC) has disclosed Accumulated Depreciation for 2 consecutive years, with $3.3 million as the latest value for Q2 2016.

  • Quarterly Accumulated Depreciation changed N/A to $3.3 million in Q2 2016 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Jun 2016, changed N/A year-over-year, with the annual reading at $2.9 million for FY2015, N/A changed from the prior year.
  • Accumulated Depreciation for Q2 2016 was $3.3 million at Cartesian Therapeutics, up from $2.9 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $3.3 million in Q2 2016, with the low at $2.9 million in Q4 2015.